Trevena, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • TRV045
    • TRV250
    • TRV734
  • Products
    • OLINVYK™ (oliceridine) injection
  • Medical Affairs
    • Investigator-Initiated Trials
    • Contact Medical Information
  • Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial Info
    • Stock Info
    • Resources
    • Governance
  • Careers
  • Contact
    • Contact Medical Information
    • Whistleblower Hotline

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
    • Presentations
    • IR Calendar
  • Financial Info
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Info
    • Quote
    • Analyst Coverage
    • IRS Form 8937
  • Resources
    • Email Alerts
    • Contacts
    • FAQ
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Governance Documents

Trevena to Present First-in-Man Study Results for Mu-Opioid Biased Ligand TRV130

Mar 18, 2013 9:00am EDT

Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure

Mar 08, 2013 9:00am EST

Trevena’s Maxine Gowen named CEO of the Year by PA Bio

Feb 08, 2013 9:00am EST

Trevena GPCR platform yields a novel mu-opioid biased ligand analgesic with side effect benefits

Jan 23, 2013 9:00am EST

Trevena Completes First-in-Human Study of TRV130, an Injectable Mu-Opioid Biased Ligand for Acute Pain

Nov 14, 2012 9:00am EST

Trevena Presents Phase 1 Clinical Data for TRV027, a β-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting

Sep 07, 2012 9:00am EDT

Trevena Angiotensin Receptor Biased Ligand Promotes Cell Survival During Acute Cardiac Injury

Sep 04, 2012 1:30pm EDT

Trevena Acute Heart Failure Drug TRV027 Unloads the Heart and Maintains Renal Function When Co-administered with Furosemide in Dog Heart Failure Model

Sep 04, 2012 1:00pm EDT

Trevena Enters Research Collaboration with Merck To Identify Novel Biased Ligand Molecules

May 02, 2012 8:30am EDT

Trevena Initiates Clinical Development of TRV130, a Biased Mu-Opioid Ligand for Severe Post-Operative Pain

Feb 13, 2012 8:30am EST
RSS
  • Prev
    • 1...
    • 22
    • 23
    • 24
    • 25
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2023 Trevena, Inc. All Rights Reserved.
    Privacy Policy Terms of Use Disclaimer Sitemap